ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1480 • 2014 ACR/ARHP Annual Meeting

    Dose Selection of GLPG0634, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 2B Studies: PK/PD and Exposure-DAS28 Modeling Approach

    Florence Namour1, Chantal Tasset2, Béatrice Vayssièrre3, Gerben van 't Klooster4, Paul Diderichsen5 and Eugène Cox6, 1102 Avenue Gaston Roussel, Galapagos SASU, Romainville, France, 2Generaal de Wittelaan L11 A3, Galapagos NV, Mechelen, Belgium, 3Galapagos SASU, Romainville, France, 4Galapagos NV, Mechelen, Belgium, 5Quantitative Solution, Breda, Netherlands, 6Quantitative Solutions, Breda, Netherlands

    Background/Purpose: GLPG0634 is an orally-available, selective Janus kinase 1 (JAK1) inhibitor. Selective inhibition of JAK1 may combine favorable safety and clinical efficacy profiles with rapid…
  • Abstract Number: 1479 • 2014 ACR/ARHP Annual Meeting

    Impact of Clinical Remission on Physical Function in Patients with Rheumatoid Arthritis Treated with ALX-0061: Post-Hoc Analysis of Phase I/II Data

    Katrien Van Beneden1, Katrien Verschueren1, Wouter Willems1, Heidi Wouters1, Joke D'Artois1, Katelijne De Swert1, Steven De Bruyn1 and Gerhard Arold2, 1Clinical Development, Ablynx nv, Zwijnaarde, Belgium, 2Medical Affairs, PRA International GmbH, Berlin, Germany

    Background/Purpose: ALX-0061 is a monovalent IL-6R targeting Nanobody, inhibiting signaling via soluble and membrane IL-6R. The safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of ALX-0061 was…
  • Abstract Number: 1478 • 2014 ACR/ARHP Annual Meeting

    Pharmacokinetics, Bioavailability and Safety of a Modified-Release Once-Daily Formulation of Tofacitinib in Healthy Volunteers

    M. Lamba1, R. Wang1, T. Fletcher2, C. Alvey1, A. Hazra1, J. Kushner1, J. Larmann1 and T. Stock2, 1Pfizer Inc, Groton, CT, 2Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The efficacy and safety of an immediate-release (IR) formulation…
  • Abstract Number: 1477 • 2014 ACR/ARHP Annual Meeting

    Overweight and Obesity Are Associated with Reduced Risk of Rheumatoid Arthritis in Men, but Not in Women

    Carl Turesson1, Ulf Bergström2, Mitra Pikwer2,3, Jan-Åke Nilsson2 and Lennart Jacobsson2,4, 1Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 2Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 3Rheumatology Unit, Mälar Hospital, Eskilstuna, Sweden, 4Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden

    Background/Purpose There are diverging results on the relation between body mass index (BMI) and risk of rheumatoid arthritis (RA). Several studies have reported different patterns…
  • Abstract Number: 1476 • 2014 ACR/ARHP Annual Meeting

    A Dose Response Relationship Between Shared Epitope and ACPA Level: But Not All SE Alleles Are Created Equal

    Jeremy Sokolove1, Lauren J. Lahey1, Catriona Wagner2, Irene Smolik3, David B. Robinson4, Elizabeth D. Ferucci5, Marianna Newkirk6, Marvin Fritzler7, William H. Robinson8 and Hani El-Gabalawy9, 1VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, 2VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, 3Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, 4Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, 5Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, 6McGill University, Montreal, QC, Canada, 7Medicine, University of Calgary, Calgary, AB, Canada, 8VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 9University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose:  Indigenous North American populations have high prevalence of seropositive RA.  The Cree/Ojibway population in Central Canada and the Alaska Native population have a high prevalence…
  • Abstract Number: 1475 • 2014 ACR/ARHP Annual Meeting

    Porphyromonas Gingivalis and Bone Turnover Biomarkers in Rheumatoid Arthritis

    Manpreet Sethi1, Anand Dusad1, Harlan Sayles2, Geoffrey Thiele3, Jeffrey Payne4, Michael J. Duryee5, Bart Hamilton6 and Ted R. Mikuls7, 1Rheumatology, University of Nebraska Medical Center, Omaha, NE, 2Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 3Int Med/Sec of Rheum/Immun, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 4College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, 5Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 6University of Nebraska Medical Centre and Omaha VA Medical Center, Omaha, NE, 7Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Periodontitis (PD) associated with P. gingivalis has been implicated as a risk factor for rheumatoid arthritis (RA).  We have previously demonstrated that RA patients…
  • Abstract Number: 1474 • 2014 ACR/ARHP Annual Meeting

    Anti-Peptidyl Arginine Deiminase 4 Antibodies in African-Americans with Rheumatoid Arthritis and  Radiographic Scores

    Iris Navarro-Millan1, Andrew Westfall2, Erika Darrah3,4, Antony Rosen5, Ted R. Mikuls6, Richard Reynolds2, Maria I. Danila7, Jeffrey R. Curtis2 and S. Louis Bridges Jr.2,8, 1Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Division of Rheumatology, The Johns Hopkins University, Baltimore, MD, 45200 Eastern Ave MFL Bldg Cntr, The Johns Hopkins University, Division of Rheumatology, Baltimore, MD, 5Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 6Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 7Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 8Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The presence of serum autoantibodies to peptidyl arginine deiminase 4 (PAD4) have been associated with erosive rheumatoid arthritis (RA) in populations that were composed…
  • Abstract Number: 1473 • 2014 ACR/ARHP Annual Meeting

    Manocept-Cy3 Localizes CD206 + Macrophages in Synovial Tissue and Fluid from Rheumatoid Arthritis Patients Differentially Compared to Controls

    Nicholas A. Young1, Larry Schlesinger2, Thomas J. Rosol3, Fred Cope4 and Wael N. Jarjour5, 1Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 2Center for Microbial Interface Biology, Department of Microbial Infection and Immunity, The Ohio State University College of Medicine, Columbus, OH, 3The Ohio State University College of Veterinary Medicine, Columbus, OH, 4Navidea Biopharmaceuticals, Dublin, OH, 5Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH

    Background/Purpose: Early identification of rheumatoid arthritis (RA) would allow aggressive treatment with disease modifying rheumatic drugs and provide a system to monitor patient responses.  Therefore,…
  • Abstract Number: 1452 • 2014 ACR/ARHP Annual Meeting

    Timing of Decisions to Adjust Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting

    Yomei Shaw1, Chung-Chou H. Chang2, Marc C. Levesque3, Julie M. Donohue4, Kaleb Michaud5,6 and Mark S. Roberts1, 1Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 2Department of Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, PA, 3Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, 4Health Policy & Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 5National Data Bank for Rheumatic Diseases, Wichita, KS, 6Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Current guidelines recommend that rheumatoid arthritis (RA) patients with poor response to their current regimen of disease modifying anti-rheumatic drugs (DMARDs) have therapy adjusted…
  • Abstract Number: 1453 • 2014 ACR/ARHP Annual Meeting

    Gastrointestinal Risk Factors and Treatment Patterns of Rheumatoid Arthritis Versus Osteoarthritis Patients in Korea

    Eun Young Lee1, Sang Heon Lee2, Hyo-Jin Kim3 and Korea RA/OA OR Group, 1Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, 2Dept of Internal Medicine, Konkuk University Hospital, Seoul, South Korea, 3Pfizer Tower, 1-11, Hoehyun-Dong 3-Ga, Jung-Gu, Seoul, South Korea

    Background/Purpose Little is known about local data of the gastrointestinal risk faocts (GI) and treatment pattenrs in rheumatoid arthritis (RA) and osteoarthritis (OA) patients. This study aimed to investigate and compare…
  • Abstract Number: 1451 • 2014 ACR/ARHP Annual Meeting

    Use of Analgesics in Patients with Knee and/or Hip Osteoarthritis: Results from the Amsterdam Osteoarthritis Cohort

    Joyce van Tunen1, Marike van der Leeden1,2, Martin van der Esch1, Leo D. Roorda1, Willem F. Lems3,4 and Joost Dekker5, 1Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, 2Rehabilitation Medicine/EMGO, VU University Medical Center, Amsterdam, Netherlands, 3Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, 4Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 5Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands

    Background/Purpose Use of analgesics is recommended by international guidelines to reduce pain complaints related to knee and/or hip osteoarthritis. Underuse of analgesics might be substantial…
  • Abstract Number: 1450 • 2014 ACR/ARHP Annual Meeting

    Spironolactone As a Novel DMARD in Rheumatoid Arthritis

    Inderjeet Verma1, Pawan Krishan2 and Ashit Syngle3, 1Deptt. of Pharmaceutical Sciences & Drug Resaerch, Punjabi University Patiala, India, Chandigarh, India, 2Deptt. of Pharmaceutical Sciences & Drug Research, Punjabi University Patiala, India, Patiala, India, 3Cardio Rheuma, Healing Touch City Clinic, Fortis Multispeciality Hospital, Chandigarh, India

    Background/Purpose: Synthetic disease-modifying antirheumatic drugs (DMARDs) though effective have limitations often requiring use of expensive parenteral biologic DMARDs in Rheumatoid Arthritis (RA). Hence there is…
  • Abstract Number: 1448 • 2014 ACR/ARHP Annual Meeting

    A Questionnaire Assessment of Knowledge about Methotrexate of Patients with Rheumatoid Arthritis

    Françoise Fayet1, Carine Savel1, Malory Rodere2, Bruno Pereira3, Dihya Abdi1, Marion Couderc Sr.4, Sylvain Mathieu5, Anne Tournadre6, Sandrine Malochet-Guinamand6, Martin Soubrier7 and Jean Jacques Dubost8, 1Rheumatology, CHU Gabriel-Montpied, Clermont-ferrand, France, 2Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France, 3Clinical research department, Clermont-Ferrand, France, 4Chu G.Montpied, Clermont Ferrand, France, 5Hopital Gabriel Montpied, Clermont Ferrand, France, 6Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, 7COMEDRA trial group, Paris, France, 8Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France

    Background/Purpose Methotrexate is the reference treatment for rheumatoid arthritis (RA).  It has potentially serious side effects which can be prevented by an improvement in patient’s…
  • Abstract Number: 1447 • 2014 ACR/ARHP Annual Meeting

    Implementing American College of Rheumatology (ACR) Quality Indicators for Rheumatoid Arthritis (RA) in the United Arab Emirates (UAE)

    Hannah Beermann, Joyce Daoud and Humeira Badsha, Dr. Humeira Badsha Medical Centre, Dubai, United Arab Emirates

    Background/Purpose Prior to the establishment of RA standards set by the ACR, a widespread discrepancy was formed between practices, which were treating patients with RA…
  • Abstract Number: 1446 • 2014 ACR/ARHP Annual Meeting

    Utility of Ultrasound in the Nuffield Orthopaedic Centre Emergency Rheumatology Clinic: Survey of Clinical Effectiveness

    Kuljeet Bhamra1, Catherine Swales1, Matthew Seymour1, Catherine McClinton1 and Peter C. Taylor2, 1Nuffield Department of orthopaedics,rheumatology and musculosketal sciences, University of Oxford, Oxford, United Kingdom, 2NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom

    Background/Purpose The aim of the survey was to evaluate the impact of clinic-based musculoskeletal ultrasonography (MSUS) on diagnosis and management of cases seen in the…
  • « Previous Page
  • 1
  • …
  • 1952
  • 1953
  • 1954
  • 1955
  • 1956
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology